## 1. Individual evaluation results

### Output_01

**Hard Gates**

| Hard Gate                                                    | Result     | Evaluation                                                                                                                                                                                                                                                                                                                                                                  |
| ------------------------------------------------------------ | ---------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| HG-1 Structure and Allowed Labels                            | PASS       | Raw output is valid JSON, conforms to the frozen schema, and uses allowed labels.                                                                                                                                                                                                                                                                                           |
| HG-2 Evidence Integrity and Quantitative Non-Fabrication     | PASS       | Material statistics and trends checked are supported by the frozen ABS input; no fabricated calculation identified.                                                                                                                                                                                                                                                         |
| HG-3 Medibank Evidence Boundary                              | PASS       | National mortality evidence is consistently separated from proposed Medibank investigation.                                                                                                                                                                                                                                                                                 |
| HG-4 Quantitative, Temporal, Missingness and Caveat Fidelity | **REVIEW** | The all-deaths proportion finding is valid, but the output does not preserve the source's unresolved cutoff inconsistency: the section text refers to registrations by 30 June while the table footnote specifies 31 July 2026. General provisional-data caveats are retained, so this is treated as a local qualification omission rather than a material factual failure. |
| HG-5 Agreed Medibank Assessment Factors                      | PASS       | All five core factors plus relevant supplementary factors are assessed.                                                                                                                                                                                                                                                                                                     |
| HG-6 Source Traceability                                     | PASS       | Findings have meaningful supporting evidence and accurate section/table locations.                                                                                                                                                                                                                                                                                          |

**Quality scores**

| Dimension                                                  |      Score /3 |
| ---------------------------------------------------------- | ------------: |
| QD-1 Important Finding Selection and Completeness          |             3 |
| QD-2 Evidence Grounding and Traceability                   |             3 |
| QD-3 Relevance Reasoning                                   |             3 |
| QD-4 Priority Reasoning and Calibration                    |             2 |
| QD-5 Uncertainty, Caveat and Unavailable-Evidence Handling |             2 |
| QD-6 Follow-up and Monitoring Usefulness                   |             3 |
| QD-7 Clarity, Concision and Output Efficiency              |             2 |
| **Weighted total**                                         | **86.7 /100** |

**Strengths:** Broad and decision-relevant evidence selection; particularly good coverage of recent mortality, multi-year virus trends, the 2025 influenza signal, age/sex, jurisdictional and Indigenous-status evidence, proportional mortality and reporting lag. Relevance reasoning clearly preserves the Medibank evidence boundary. Follow-up questions are specific and tied to age, geography, claims/utilisation and revisions.

**Weaknesses:** The `Medium Priority` judgement is defensible but somewhat stronger than the evidence benchmark: the rationale itself acknowledges low/stable latest mortality, provisional data, and absence of utilisation, cost or Medibank exposure. The RSV underlying-versus-contributing distinction is also not foregrounded despite being a useful interpretation point.

**Material factual or methodological errors:** No confirmed material factual error. The omitted all-deaths registration-cutoff inconsistency requires review.

---

### Output_02

**Hard Gates**

| Hard Gate                                                    | Result | Evaluation                                                                                                                     |
| ------------------------------------------------------------ | ------ | ------------------------------------------------------------------------------------------------------------------------------ |
| HG-1 Structure and Allowed Labels                            | PASS   | Valid schema-conformant JSON and allowed labels.                                                                               |
| HG-2 Evidence Integrity and Quantitative Non-Fabrication     | PASS   | Reported values, historical comparisons and timeliness statistics are source-supported.                                        |
| HG-3 Medibank Evidence Boundary                              | PASS   | Does not convert national mortality patterns into Medibank facts.                                                              |
| HG-4 Quantitative, Temporal, Missingness and Caveat Fidelity | PASS   | Material periods, provisional status, Indigenous geographic scope and historical timeliness basis are preserved appropriately. |
| HG-5 Agreed Medibank Assessment Factors                      | PASS   | Core factors and several supplementary factors are explicitly applied.                                                         |
| HG-6 Source Traceability                                     | PASS   | Finding-to-section linkage is clear and accurate.                                                                              |

**Quality scores**

| Dimension                                                  |      Score /3 |
| ---------------------------------------------------------- | ------------: |
| QD-1 Important Finding Selection and Completeness          |             3 |
| QD-2 Evidence Grounding and Traceability                   |             3 |
| QD-3 Relevance Reasoning                                   |             3 |
| QD-4 Priority Reasoning and Calibration                    |             2 |
| QD-5 Uncertainty, Caveat and Unavailable-Evidence Handling |             3 |
| QD-6 Follow-up and Monitoring Usefulness                   |             3 |
| QD-7 Clarity, Concision and Output Efficiency              |             3 |
| **Weighted total**                                         | **93.3 /100** |

**Strengths:** Particularly strong balance of evidence and caveats. It captures the elevated 2025 influenza signal, COVID/influenza crossover periods, Indigenous disparities and reporting lag while remaining relatively economical. Missing utilisation, cost and private-health evidence is handled explicitly rather than inferred.

**Weaknesses:** RSV's distinction as predominantly a contributing rather than underlying cause is not captured, and the all-deaths proportion evidence is omitted. Neither omission materially prevents a sound assessment. `Informational` may slightly underweight the elevated 2025 influenza and Indigenous mortality signals.

**Material factual or methodological errors:** None identified.

---

### Output_03

**Hard Gates**

| Hard Gate                                                    | Result | Evaluation                                                                                                 |
| ------------------------------------------------------------ | ------ | ---------------------------------------------------------------------------------------------------------- |
| HG-1 Structure and Allowed Labels                            | PASS   | Valid JSON, schema compliant, allowed labels only.                                                         |
| HG-2 Evidence Integrity and Quantitative Non-Fabrication     | PASS   | Numerical and trend claims are supported by the frozen source.                                             |
| HG-3 Medibank Evidence Boundary                              | PASS   | Medibank implications remain hypothetical/internal-investigation questions.                                |
| HG-4 Quantitative, Temporal, Missingness and Caveat Fidelity | PASS   | Major temporal and methodological qualifications are retained.                                             |
| HG-5 Agreed Medibank Assessment Factors                      | PASS   | All five core factors are considered; supplementary evidence-strength/actionability factors are also used. |
| HG-6 Source Traceability                                     | PASS   | Source locations are accurate and claims are traceable.                                                    |

**Quality scores**

| Dimension                                                  |      Score /3 |
| ---------------------------------------------------------- | ------------: |
| QD-1 Important Finding Selection and Completeness          |             2 |
| QD-2 Evidence Grounding and Traceability                   |             3 |
| QD-3 Relevance Reasoning                                   |             3 |
| QD-4 Priority Reasoning and Calibration                    |             2 |
| QD-5 Uncertainty, Caveat and Unavailable-Evidence Handling |             3 |
| QD-6 Follow-up and Monitoring Usefulness                   |             3 |
| QD-7 Clarity, Concision and Output Efficiency              |             3 |
| **Weighted total**                                         | **88.3 /100** |

**Strengths:** Strong treatment of the main COVID/influenza temporal patterns, historical influenza comparator, population differences and reporting lag. It clearly states what mortality data cannot establish about utilisation, morbidity, costs or Medibank-specific effects.

**Weaknesses:** RSV-specific evidence is comparatively thin: the important contributing-cause feature and multi-year RSV trend are not developed. The explicit private-health relevance criterion is not included as a separate row, although the boundary is addressed elsewhere. `Informational` is plausible but gives less weight than the frozen benchmark to the 2025 influenza signal.

**Material factual or methodological errors:** None identified.

---

### Output_04

**Hard Gates**

| Hard Gate                                                    | Result     | Evaluation                                                                                                                                                   |
| ------------------------------------------------------------ | ---------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| HG-1 Structure and Allowed Labels                            | PASS       | Valid, schema-conformant JSON with permitted labels.                                                                                                         |
| HG-2 Evidence Integrity and Quantitative Non-Fabrication     | PASS       | Findings, including RSV decomposition and Indigenous rate comparisons, are supported.                                                                        |
| HG-3 Medibank Evidence Boundary                              | PASS       | Medibank implications are explicitly conditional and framed as investigation.                                                                                |
| HG-4 Quantitative, Temporal, Missingness and Caveat Fidelity | **REVIEW** | Its all-deaths percentage finding does not surface the source's 30 June versus 31 July registration-cutoff inconsistency. Other relevant caveats are strong. |
| HG-5 Agreed Medibank Assessment Factors                      | PASS       | Comprehensive use of core and supplementary factors.                                                                                                         |
| HG-6 Source Traceability                                     | PASS       | Source locations are specific and accurate.                                                                                                                  |

**Quality scores**

| Dimension                                                  |      Score /3 |
| ---------------------------------------------------------- | ------------: |
| QD-1 Important Finding Selection and Completeness          |             3 |
| QD-2 Evidence Grounding and Traceability                   |             3 |
| QD-3 Relevance Reasoning                                   |             3 |
| QD-4 Priority Reasoning and Calibration                    |             2 |
| QD-5 Uncertainty, Caveat and Unavailable-Evidence Handling |             2 |
| QD-6 Follow-up and Monitoring Usefulness                   |             3 |
| QD-7 Clarity, Concision and Output Efficiency              |             2 |
| **Weighted total**                                         | **86.7 /100** |

**Strengths:** Strong coverage of COVID seasonality, influenza, RSV contributing-cause evidence, age, jurisdiction, Indigenous rates, total-death proportions and reporting lag. The Medibank assessment is especially explicit about utilisation, cost, private-health relevance, evidence strength and actionability.

**Weaknesses:** The important 1,489 influenza deaths in 2025 versus the 2017/2019 high-influenza comparators is not selected explicitly. The `Medium Priority` rationale is well qualified but reads largely as a case for monitoring and investigation rather than a clearly stronger priority signal.

**Material factual or methodological errors:** No confirmed material factual error. The omitted all-deaths cutoff conflict requires review.

---

### Output_05

**Hard Gates**

| Hard Gate                                                    | Result     | Evaluation                                                                                                                              |
| ------------------------------------------------------------ | ---------- | --------------------------------------------------------------------------------------------------------------------------------------- |
| HG-1 Structure and Allowed Labels                            | PASS       | Valid schema-compliant JSON and allowed categories.                                                                                     |
| HG-2 Evidence Integrity and Quantitative Non-Fabrication     | PASS       | Material claims and values are supported.                                                                                               |
| HG-3 Medibank Evidence Boundary                              | PASS       | Public mortality evidence is not presented as Medibank-specific experience.                                                             |
| HG-4 Quantitative, Temporal, Missingness and Caveat Fidelity | **REVIEW** | The all-deaths finding omits the source's conflicting 30 June/31 July registration-cutoff wording. Otherwise caveat handling is strong. |
| HG-5 Agreed Medibank Assessment Factors                      | PASS       | Full core-factor assessment plus private-health, emerging-treatment, reliability and actionability considerations.                      |
| HG-6 Source Traceability                                     | PASS       | Material findings are readily traceable to the supplied ABS sections.                                                                   |

**Quality scores**

| Dimension                                                  |      Score /3 |
| ---------------------------------------------------------- | ------------: |
| QD-1 Important Finding Selection and Completeness          |             3 |
| QD-2 Evidence Grounding and Traceability                   |             3 |
| QD-3 Relevance Reasoning                                   |             3 |
| QD-4 Priority Reasoning and Calibration                    |             2 |
| QD-5 Uncertainty, Caveat and Unavailable-Evidence Handling |             2 |
| QD-6 Follow-up and Monitoring Usefulness                   |             3 |
| QD-7 Clarity, Concision and Output Efficiency              |             2 |
| **Weighted total**                                         | **86.7 /100** |

**Strengths:** Very good selection of high-value signals: COVID decline, historical influenza elevation, COVID/influenza crossover, RSV contributing mortality, age/sex, jurisdiction and Indigenous patterns. Follow-up is specific and explicitly preserves the national-versus-Medibank boundary.

**Weaknesses:** Reporting lag is discussed in caveats and assessment but is not retained as a dedicated finding despite its significance for the newest data. `Medium Priority` is somewhat stronger than the frozen benchmark despite explicit acknowledgement of low recent levels and absent utilisation/cost/private-health evidence.

**Material factual or methodological errors:** No confirmed material factual error. Local caveat omission concerning the all-deaths cutoff requires review.

---

### Output_06

**Hard Gates**

| Hard Gate                                                    | Result   | Evaluation                                                                                                                                                                                                                                                                                        |
| ------------------------------------------------------------ | -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| HG-1 Structure and Allowed Labels                            | PASS     | Valid JSON and schema compliant.                                                                                                                                                                                                                                                                  |
| HG-2 Evidence Integrity and Quantitative Non-Fabrication     | PASS     | The selected findings themselves are source-supported; no fabricated quantitative value identified.                                                                                                                                                                                               |
| HG-3 Medibank Evidence Boundary                              | PASS     | Medibank claims/utilisation/cost effects are correctly treated as unknown.                                                                                                                                                                                                                        |
| HG-4 Quantitative, Temporal, Missingness and Caveat Fidelity | **FAIL** | `comparison_period` is stated as `"2022-2025, depending on the measure reported"` even though the output itself contains multiple explicit 2026 comparisons and the frozen input's central recent evidence is from 2026. This is a materially incorrect temporal metadata field under AC-06/HG-4. |
| HG-5 Agreed Medibank Assessment Factors                      | PASS     | The five core factors are represented.                                                                                                                                                                                                                                                            |
| HG-6 Source Traceability                                     | PASS     | Selected findings have accurate source locations.                                                                                                                                                                                                                                                 |

**Quality scores**

| Dimension                                                  |      Score /3 |
| ---------------------------------------------------------- | ------------: |
| QD-1 Important Finding Selection and Completeness          |             1 |
| QD-2 Evidence Grounding and Traceability                   |             2 |
| QD-3 Relevance Reasoning                                   |             3 |
| QD-4 Priority Reasoning and Calibration                    |             1 |
| QD-5 Uncertainty, Caveat and Unavailable-Evidence Handling |             2 |
| QD-6 Follow-up and Monitoring Usefulness                   |             2 |
| QD-7 Clarity, Concision and Output Efficiency              |             2 |
| **Weighted total**                                         | **60.0 /100** |

**Strengths:** Selected findings are concise, source-grounded and easy to trace. The relevance reasoning correctly treats the evidence as an external mortality signal rather than proof of Medibank demand or costs. The main recent-data caveats are retained.

**Weaknesses:** Important countervailing evidence is omitted: especially the 1,489 influenza underlying-cause deaths in 2025 exceeding the 2017 and 2019 high-influenza comparators, the COVID/influenza crossover periods, and the quantified registration-lag evidence. Consequently, the priority rationale is disproportionately driven by low/stable recent monthly observations. Concision therefore comes at the cost of material decision-relevant evidence.

**Material factual or methodological errors:** Material temporal metadata error in `comparison_period`. Evidence-selection incompleteness also materially weakens priority calibration, although it is not itself a fabricated fact.

---

## 2. Cross-run consistency analysis

**Relevance decision consistency:** Strong. All six outputs return `Relevant`, matching the central interpretation of the frozen benchmark. All six also consistently state that national ABS mortality evidence does not establish Medibank-specific claims, utilisation, costs or member effects.

**Priority category consistency:** Weak. The six executions divide exactly into two groups: Outputs 01, 04 and 05 return `Medium Priority`; Outputs 02, 03 and 06 return `Informational`. No run returns the frozen reference benchmark of `Watchlist`. Because the rubric deliberately avoids fixed thresholds, the one-category differences are not automatically errors. However, the 50/50 split demonstrates material instability in priority calibration on identical evidence. Outputs 01/04/05 tend to place greater weight on clinical significance and multi-year changes; Outputs 02/03/06 place greater weight on low recent mortality, absent utilisation/cost evidence and provisional status.

**Factual consistency:** Generally strong. Where the same evidence is selected, figures such as COVID-19 68/68 in May–June 2026, influenza 13/24, NSW/Victoria COVID-19 counts, Queensland influenza/RSV counts, and Indigenous COVID-19 trends remain stable. No contradictory numerical claims were identified between runs. The main exception is Output_06's inaccurate `comparison_period` metadata.

**Finding-selection consistency:** Moderate rather than strong. Recent COVID-19 mortality, older-age concentration, jurisdictional patterns and Indigenous evidence recur broadly. However, selection of important counter-signals varies materially. Historical 2025 influenza elevation is prominent in Outputs 01, 02, 03 and 05 but not adequately represented in Outputs 04 or 06. RSV's contributing-cause significance is explicit in Outputs 04 and 05 and partly in 06, but absent from 01–03. Reporting lag is an explicit finding in 01–04 but not 05–06. Output_06 has the narrowest evidence set and is the only run where the omissions materially affect the priority reasoning.

**Schema compliance consistency:** Strong. All six raw outputs parse as JSON and validate against the frozen corrected schema. All use allowed relevance and priority categories.

**Unsupported-inference consistency:** Strong. No run asserts unsupported Medibank prevalence, claims, utilisation, cost, coverage or operational effects. Follow-up suggestions are consistently framed as checks or investigations. There is therefore no recurring unsupported-Medibank-inference failure.

**Score range and variation:** Scores range from **60.0 to 93.3**, a **33.3-point range**, with a six-run mean of approximately **83.6**. Five runs cluster much more tightly at **86.7–93.3**; Output_06 is the clear low outlier because of its HG-4 failure and materially narrower evidence selection.

---

## 3. Blinded summary table

| Output    | Hard Gates                     | Relevance | Priority        | Weighted Score /100 | Key issue(s)                                                                                   |
| --------- | ------------------------------ | --------- | --------------- | ------------------: | ---------------------------------------------------------------------------------------------- |
| Output_01 | HG-4 REVIEW; all others PASS   | Relevant  | Medium Priority |            **86.7** | All-deaths cutoff inconsistency omitted; Medium calibration somewhat stronger than benchmark   |
| Output_02 | All PASS                       | Relevant  | Informational   |            **93.3** | Informational may underweight 2025 influenza/Indigenous signals; RSV contributing role omitted |
| Output_03 | All PASS                       | Relevant  | Informational   |            **88.3** | RSV evidence comparatively incomplete; Informational calibration somewhat conservative         |
| Output_04 | HG-4 REVIEW; all others PASS   | Relevant  | Medium Priority |            **86.7** | All-deaths cutoff inconsistency omitted; historical high-influenza comparator not foregrounded |
| Output_05 | HG-4 REVIEW; all others PASS   | Relevant  | Medium Priority |            **86.7** | All-deaths cutoff inconsistency omitted; reporting lag not retained as dedicated finding       |
| Output_06 | **HG-4 FAIL**; all others PASS | Relevant  | Informational   |            **60.0** | Incorrect comparison-period metadata; material evidence omissions weaken priority calibration  |

## 4. Evaluation notes

1. **Priority calibration requires human review.** The frozen materials explicitly provide no universal threshold separating `Medium Priority`, `Watchlist` and `Informational`. The frozen reference selects `Watchlist`, but it is an evaluation anchor rather than a mandatory label. Accordingly, the Medium and Informational labels above were scored on the quality and balance of their reasoning rather than treated as wrong merely for differing from the reference. The six-run 3-versus-3 split nevertheless indicates a genuine consistency problem.

2. **Outputs 01, 04 and 05 — HG-4 REVIEW:** Each includes the all-deaths proportion evidence while omitting the source's unresolved contradiction between the section's “registered by 30 June” wording and the table footnote's “registered by 31 July 2026.” Because the numerical findings remain correct and provisional-data caveats are otherwise retained, this was classified `REVIEW`, not `FAIL`. A human evaluator could reasonably decide that the general provisional caveat is sufficient and upgrade these to PASS if that source inconsistency is judged immaterial to the particular finding.

3. **Output_06 — HG-4 FAIL:** The stated comparison period ends in 2025 despite substantial 2026 evidence being reported in the output. Under the frozen HG-4 wording, a materially wrong period is a direct failure condition. This is distinct from merely giving a broad or non-exhaustive comparison-period description.

4. **Age-standardised-rate units:** The frozen source supplies the reported rate values but does not state an explicit scaling unit. Outputs that use values such as 26.6, 16.5, 12.3 and 4.7 without inventing “per 100,000” or another denominator were therefore not penalised.

5. **Finding-count differences were not penalised by themselves.** Additional source-supported findings were accepted, and no output was required to reproduce the exact reference-answer finding set. Penalties were applied only where omission materially reduced decision-relevant coverage or altered the resulting assessment.
